O	0	7	Effects
O	8	10	of
O	11	13	an
O	14	16	18
O	16	17	-
O	17	21	week
B-intervention	22	30	exercise
O	31	40	programme
O	41	48	started
O	49	54	early
O	55	61	during
O	62	68	breast
O	69	75	cancer
O	76	85	treatment
O	85	86	:
O	87	88	a
O	89	99	randomised
O	100	110	controlled
O	111	116	trial
O	116	117	.

O	118	126	Exercise
O	127	134	started
O	135	142	shortly
O	143	148	after
O	149	155	breast
O	156	162	cancer
O	163	172	diagnosis
O	173	178	might
O	179	186	prevent
O	187	189	or
O	190	198	diminish
O	199	206	fatigue
O	207	217	complaints
O	217	218	.

O	219	222	The
O	223	231	Physical
O	232	240	Activity
O	241	247	during
O	248	254	Cancer
O	255	264	Treatment
O	265	266	(
O	266	270	PACT
O	270	271	)
O	272	277	study
O	278	281	was
O	282	290	designed
O	291	293	to
O	294	303	primarily
O	304	311	examine
O	312	315	the
O	316	323	effects
O	324	326	of
O	327	329	an
O	330	332	18
O	332	333	-
O	333	337	week
O	338	346	exercise
O	347	359	intervention
O	359	360	,
O	361	368	offered
O	369	371	in
O	372	375	the
O	376	381	daily
O	382	390	clinical
O	391	399	practice
O	400	407	setting
O	408	411	and
O	412	420	starting
O	421	427	within
O	428	429	6
O	430	435	weeks
O	436	441	after
O	442	451	diagnosis
O	451	452	,
O	453	455	on
O	456	466	preventing
O	467	469	an
O	470	478	increase
O	479	481	in
O	482	489	fatigue
O	489	490	.

O	491	495	This
O	496	501	multi
O	501	502	-
O	502	508	centre
O	509	519	controlled
O	520	525	trial
O	526	534	randomly
O	535	543	assigned
B-total-participants	544	547	204
O	548	554	breast
O	555	561	cancer
O	562	570	patients
O	571	573	to
B-control	574	579	usual
I-control	580	584	care
O	585	586	(
O	586	587	n
O	588	589	=
B-control-participants	590	593	102
O	593	594	)
O	595	597	or
O	598	608	supervised
O	609	616	aerobic
O	617	620	and
O	621	631	resistance
O	632	640	exercise
O	641	642	(
O	642	643	n
O	644	645	=
B-intervention-participants	646	649	102
O	649	650	)
O	650	651	.

O	652	654	By
O	655	661	design
O	661	662	,
O	663	666	all
O	667	675	patients
O	676	684	received
O	685	697	chemotherapy
O	698	705	between
O	706	714	baseline
O	715	718	and
O	719	721	18
O	722	727	weeks
O	727	728	.

B-outcome-Measure	729	736	Fatigue
O	737	738	(
O	738	739	i
O	739	740	.
O	740	741	e
O	741	742	.
O	742	743	,
O	744	751	primary
O	752	759	outcome
O	760	762	at
O	763	765	18
O	766	771	weeks
O	771	772	)
O	772	773	,
B-outcome-Measure	774	781	quality
I-outcome-Measure	782	784	of
I-outcome-Measure	785	789	life
O	789	790	,
B-outcome-Measure	791	798	anxiety
O	798	799	,
B-outcome-Measure	800	810	depression
O	810	811	,
O	812	815	and
B-outcome-Measure	816	824	physical
I-outcome-Measure	825	832	fitness
O	833	837	were
O	838	846	measured
O	847	849	at
O	850	852	18
O	853	856	and
O	857	859	36
O	860	865	weeks
O	865	866	.

O	867	876	Intention
O	876	877	-
O	877	879	to
O	879	880	-
O	880	885	treat
O	886	891	mixed
O	892	898	linear
O	899	904	model
O	905	913	analyses
O	914	920	showed
O	921	925	that
B-outcome	926	934	physical
I-outcome	935	942	fatigue
O	943	952	increased
O	953	966	significantly
O	967	971	less
O	972	978	during
O	979	985	cancer
O	986	995	treatment
O	996	998	in
O	999	1002	the
O	1003	1015	intervention
O	1016	1021	group
O	1022	1030	compared
O	1031	1033	to
O	1034	1041	control
O	1042	1043	(
O	1043	1047	mean
O	1048	1055	between
O	1055	1056	-
O	1056	1061	group
O	1062	1073	differences
O	1074	1076	at
O	1077	1079	18
O	1080	1085	weeks
O	1085	1086	:
O	1087	1088	-
O	1088	1089	1
O	1089	1090	.
O	1090	1091	3
O	1091	1092	;
O	1093	1095	95
O	1096	1097	%
O	1098	1100	CI
O	1101	1102	-
O	1102	1103	2
O	1103	1104	.
O	1104	1105	5
O	1106	1108	to
O	1109	1110	-
O	1110	1111	0
O	1111	1112	.
O	1112	1113	1
O	1113	1114	;
O	1115	1121	effect
O	1122	1126	size
O	1127	1128	-
O	1128	1129	0
O	1129	1130	.
O	1130	1132	30
O	1132	1133	)
O	1133	1134	.

O	1135	1142	Results
O	1143	1146	for
B-outcome	1147	1154	general
I-outcome	1155	1162	fatigue
O	1163	1167	were
O	1168	1178	comparable
O	1179	1182	but
O	1183	1186	did
O	1187	1190	not
O	1191	1196	reach
O	1197	1208	statistical
O	1209	1221	significance
O	1222	1223	(
O	1223	1224	-
O	1224	1225	1
O	1225	1226	.
O	1226	1227	0
O	1227	1228	,
O	1229	1231	95
O	1231	1232	%
O	1232	1234	CI
O	1235	1236	-
O	1236	1237	2
O	1237	1238	.
O	1238	1239	1
O	1239	1240	;
O	1241	1242	0
O	1242	1243	.
O	1243	1244	1
O	1244	1245	;
O	1246	1252	effect
O	1253	1257	size
O	1258	1259	-
O	1259	1260	0
O	1260	1261	.
O	1261	1263	23
O	1263	1264	)
O	1264	1265	.

O	1266	1268	At
O	1269	1271	18
O	1272	1277	weeks
O	1277	1278	,
B-outcome	1279	1289	submaximal
I-outcome	1290	1307	cardiorespiratory
I-outcome	1308	1315	fitness
I-outcome	1316	1319	and
I-outcome	1320	1327	several
I-outcome	1328	1334	muscle
I-outcome	1335	1343	strength
I-outcome	1344	1349	tests
O	1350	1351	(
O	1351	1354	leg
O	1355	1364	extension
O	1365	1368	and
O	1369	1376	flexion
O	1376	1377	)
O	1378	1382	were
O	1383	1396	significantly
O	1397	1403	higher
O	1404	1406	in
O	1407	1410	the
O	1411	1423	intervention
O	1424	1429	group
O	1430	1438	compared
O	1439	1441	to
O	1442	1449	control
O	1449	1450	,
O	1451	1458	whereas
B-outcome	1459	1463	peak
I-outcome	1464	1470	oxygen
I-outcome	1471	1477	uptake
O	1478	1481	did
O	1482	1485	not
O	1486	1492	differ
O	1493	1500	between
O	1501	1507	groups
O	1507	1508	.

O	1509	1511	At
O	1512	1514	36
O	1515	1520	weeks
O	1521	1526	these
O	1527	1538	differences
O	1539	1543	were
O	1544	1546	no
O	1547	1553	longer
O	1554	1567	statistically
O	1568	1579	significant
O	1579	1580	.

B-outcome	1581	1588	Quality
I-outcome	1589	1591	of
I-outcome	1592	1596	life
I-outcome	1597	1605	outcomes
O	1606	1614	favoured
O	1615	1618	the
O	1619	1627	exercise
O	1628	1633	group
O	1634	1637	but
O	1638	1642	were
O	1643	1646	not
O	1647	1660	significantly
O	1661	1670	different
O	1671	1678	between
O	1679	1685	groups
O	1685	1686	.

O	1687	1688	A
O	1689	1699	supervised
O	1700	1702	18
O	1702	1703	-
O	1703	1707	week
O	1708	1716	exercise
O	1717	1726	programme
O	1727	1734	offered
O	1735	1740	early
O	1741	1743	in
O	1744	1751	routine
O	1752	1756	care
O	1757	1763	during
O	1764	1772	adjuvant
O	1773	1779	breast
O	1780	1786	cancer
O	1787	1796	treatment
O	1797	1803	showed
O	1804	1812	positive
O	1813	1820	effects
O	1821	1823	on
B-outcome	1824	1832	physical
I-outcome	1833	1840	fatigue
O	1840	1841	,
B-outcome	1842	1852	submaximal
I-outcome	1853	1870	cardiorespiratory
I-outcome	1871	1878	fitness
O	1878	1879	,
O	1880	1883	and
B-outcome	1884	1890	muscle
I-outcome	1891	1899	strength
O	1899	1900	.

O	1901	1909	Exercise
O	1910	1915	early
O	1916	1922	during
O	1923	1932	treatment
O	1933	1935	of
O	1936	1942	breast
O	1943	1949	cancer
O	1950	1953	can
O	1954	1956	be
O	1957	1968	recommended
O	1968	1969	.

O	1970	1972	At
O	1973	1975	36
O	1976	1981	weeks
O	1981	1982	,
O	1983	1988	these
O	1989	1996	effects
O	1997	2001	were
O	2002	2004	no
O	2005	2011	longer
O	2012	2025	statistically
O	2026	2037	significant
O	2037	2038	.

O	2039	2043	This
O	2044	2049	might
O	2050	2054	have
O	2055	2059	been
O	2060	2066	caused
O	2067	2069	by
O	2070	2073	the
O	2074	2081	control
O	2082	2094	participants
O	2094	2095	'
O	2096	2100	high
O	2101	2109	physical
O	2110	2118	activity
O	2119	2125	levels
O	2126	2132	during
O	2133	2139	follow
O	2139	2140	-
O	2140	2142	up
O	2142	2143	.

O	2144	2151	Current
O	2152	2162	Controlled
O	2163	2169	Trials
O	2170	2184	ISRCTN43801571
O	2184	2185	,
O	2186	2191	Dutch
O	2192	2197	Trial
O	2198	2206	Register
O	2207	2214	NTR2138
O	2214	2215	.

O	2216	2221	Trial
O	2222	2232	registered
O	2233	2235	on
O	2236	2244	December
O	2245	2248	9th
O	2248	2249	,
O	2250	2254	2009
O	2254	2255	.
